Co-founder of Trinomab, Dr. Liao holds a Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill (UNC-CH). Formerly a professor at Duke University School of Medicine and the Duke Human Vaccine Institute, he has over 40 years of pioneering research in virology, immunology, vaccine development, and humoral immune response mechanisms. A globally renowned immunologist and virologist, Dr. Liao played a key role in China's first isolation of the epidemic hemorrhagic fever virus. His outstanding work spans HIV infection, HIV vaccine development, research on antibody protection mechanisms, and studies on antibody profiles following influenza virus vaccination and infection worldwide. He has published over 200 high-impact research papers in top-tier academic journals including Nature, Science, and Cell, with expertise in cutting-edge monoclonal antibody theories and technologies.
He leads the overall drug development, coordinating the entire drug development process including preclinical and clinical research, process development, and registration strategy formulation.
Co-founder of Trinomab, Mr. Zheng holds an MBA from Peking University HSBC Business School and brings over 20 years of profound industry expertise. He possesses extensive experience in biopharmaceutical commercialization, corporate operations management, and strategic planning. As former General Manager of Beijing Chia Tai Lvzhou Pharmaceutical Co., Ltd., he successfully led the end-to-end commercialization of multiple anti-infective drugs, achieving both extensive market penetration and breakthrough commercial success for the product pipeline.
In 2015, he co-founded Trinomab with Dr. Liao Huaxin, overseeing the company's strategic development planning, overall operations management, and investment/financing initiatives. Under his leadership, the company has established differentiated competitive advantages in the field of fully human monoclonal antibody R&D, while accelerating the transformation of innovative drug technologies into industrial applications.
